Roivant Sciences Ltd.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Roivant Sciences Ltd. Q1 2026 Earnings Call Summary
Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call
Roivant Sciences Q1 Earnings Call Highlights
Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie
Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ...
Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.
Congressional Trades in $ROIV
No disclosed congressional trades found in $ROIV.
Insider Trades (Form 4)
Venker Eric
MOMTAZEE JAMES C
Epperly Melissa B,
Oren Ilan
Torti Frank
Sukhatme Mayukh
Epperly Melissa B,
MANCHESTER KEITH S
Key People
Oren Ilan
Director
MOMTAZEE JAMES C
Director
Torti Frank
President and Vant Chair
QVT Financial LP
Insider
MANCHESTER KEITH S
Director
Gold Daniel Allen
Director
Epperly Melissa B
Director
Sukhatme Mayukh
President & CIO
Venker Eric
President & Immunovant CEO
Pulik Richard
CFO
Humes Jennifer
Chief Accounting Officer
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro